Literature DB >> 2546701

Serum monoclonal antibodies derived from patients with multiple myeloma react with mycobacterial phosphoinositides and nuclear antigens.

D Buskila1, M Abu-Shakra, H Amital-Teplizki, A R Coates, M Krupp, S Sukenik, Y Shoenfeld.   

Abstract

The sera of 46 patients with multiple myeloma were examined for the presence of anti-tuberculosis (TB) glycolipids antibodies. In positive sera samples, anti-polynucleotides, anti-histones, anti-cardiolipin, anti-Sm and anti-RNP activities were sought. Antibodies against three different mycobacterial glycolipids were detected in 10 of the 46 sera. Three (P429, P557, P5) showed high titres of antibodies against all three different TB glycolipids. Of the 10 reactive samples, two antibodies were purified (P429, P557). P557 reacted with various polynucleotides and other antigens tested (Sm, RNP, cardiolipin, histones). One immunoglobulin (P207) which showed high activity against Sm and RNP had no activity against TB glycolipids and was employed as a control. The cross-reactivity between mycobacterial glycolipids and the nuclear antigens was further established by bi-directional competition assays with P429 and P557. Our study shows a high incidence (22%) of anti-TB glycolipids antibodies in sera of patients with monoclonal gammopathies, some of which show anti-DNA and other anti-nuclear antigens activities. This is additional evidence for the mycobacterial-nuclear antigen cross-reactivity which may suggest a possible role of infection (e.g., tuberculosis) in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546701      PMCID: PMC1541880     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  A monoclonal macroglobulin with antinuclear activity.

Authors:  L Intrator; C Andre; C Chenal; C Sultan
Journal:  J Clin Pathol       Date:  1979-05       Impact factor: 3.411

Review 2.  Mycobacteria and autoimmunity.

Authors:  Y Shoenfeld; D A Isenberg
Journal:  Immunol Today       Date:  1988-06

3.  Antibody activity of human myeloma globulins.

Authors:  M Seligmann; J C Brouet
Journal:  Semin Hematol       Date:  1973-04       Impact factor: 3.851

4.  A human IgG myeloma protein with anti- 2 macroglobulin antibody activity.

Authors:  M Seligmann; C Sassy; A Chevalier
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

5.  Transient autoimmune hemolytic anemia and pulmonary tuberculosis.

Authors:  H W Murray
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

6.  Plasma cell dyscrasia. Analysis of 423 patients.

Authors:  A I Pick; Y Shoenfeld; R Frohlichmann; H Weiss; D Vana; S Schreibman
Journal:  JAMA       Date:  1979-05-25       Impact factor: 56.272

7.  Production of autoantibodies by human-human hybridomas.

Authors:  Y Shoenfeld; S C Hsu-Lin; J E Gabriels; L E Silberstein; B C Furie; B Furie; B D Stollar; R S Schwartz
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

8.  Purification of serologically active phosphoinositides of Mycobacterium tuberculosis.

Authors:  M C Pangborn; J A McKinney
Journal:  J Lipid Res       Date:  1966-09       Impact factor: 5.922

9.  A transient monoclonal human IgG1 kappa protein with anti-thyroglobulin activity: lack of cross-idiotypy with polyclonal anti-thyroglobulin antibodies.

Authors:  T E Michaelsen; P I Gaarder; L Kornstad
Journal:  Clin Exp Immunol       Date:  1981-11       Impact factor: 4.330

10.  Common individual antigenic determinants in five of eight BALB-c IgA myeloma proteins that bind phosphoryl choline.

Authors:  M Potter; R Lieberman
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  4 in total

1.  Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.

Authors:  D D Biggs; P Kraj; J Goldman; L Jefferies; C Carchidi; K Anderson; L E Silberstein
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

2.  The detection of antithyroglobulin activity in human serum monoclonal immunoglobulins (monoclonal gammopathies).

Authors:  N Yativ; D Buskila; M Blank; C L Burek; N R Rose; Y Shoenfeld
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Pathogenic natural anti-cardiolipin antibodies: the experience from monoclonal gammopathy.

Authors:  J Cohen; R Bakimer; M Blank; G Valesini; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

4.  Heavy chain deposition disease presenting with raised anti-GBM antibody levels; a case report.

Authors:  Michael Turner; Anna Crawford; Claire Winterbottom; Oliver Flossmann; Bassam Alchi; Maria Soares; Umanath Bhandary
Journal:  BMC Nephrol       Date:  2020-05-12       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.